wang hanlu 2015.9.6 advance in research of aptamers and related drugs
Post on 01-Jan-2016
221 Views
Preview:
TRANSCRIPT
WANG HANLU2015 9 6
Advance in research of aptamers and related drugs
Aptamer
Aptamers are oligonucleotides such as RNA and single-strand deoxyribonucleic acid (ssDNA) or peptide molecules that can bind to their targets with high affinity and specificity due to their specific three-dimensional structures
Advantages of aptamers
Aptamers are produced chemically in a readily scalable process Chemical production process is not prone to viral or bacterial
contamination Non-immunogenic Smaller size allows more efficient entry into biological
compartments
The annual trends in the number of publications of aptamers-related research The term ldquoaptamerrdquo has been utilized for literature search on Thomson Reuters Web of Science
Aptamers in research
ELLINGTON AD SZOSTAK JW In vitro selection of RNA molecules that bind specific ligands[ J] Nature 1990 346( 6287) 818- 822TUERK CGOLD L Systematic evolution of ligands by exponential enrichment RNA ligands to bacteriophage-T4 DNA polymerase[ J] Science1990 249( 4968) 505- 510
SELEX (Systematic evolution of ligands by exponential enrichment)bull First reported by both Goldrsquos group and Szostakrsquos group in 1990
bull SELEX experiment a random sequence oligonucleotide library is synthesized that spans 20ndash100 residues in length and each nucleotide is flanked by constant sequences
bull The pool will frequently contain between 1 times 1013 to 1 times1015
members
Aptamer discovery process
Song K M Aptamers and their biological applications Sensors (Basel)12 612-31(2012)
Various application fields of aptamers
Aptamers in the Clinical Pipeline
JELLINEK DGREEN LSBELL Cet al Inhibition of receptor-binding by high-affinity RNA ligands to vascular endothelial growth-factor[J] Biochemistry199433 ( 34 ) 10450 - 10456 RUCKMAN JGREEN LSBEESON Jet al 2-fluoropyrimi- dine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor ( VEGF ( 165 ) ) -inhibition of receptor binding and VEGF-induced vascular permeability through interac- tions requiring the exon 7-encoded domain[J] J Biol Chem 1998273( 32) 20556 - 20567DlsquoAMICO DJMASONSON HNPATEL Met al Pegaptanib sodium for neovascular age-related macular degeneration-Two-year safety results of the two prospective multicenter controlled clinical trials[J] Ophthalmology2006113( 6) 992 - 1001
Pegaptanibmdashmdashanti-VEGF aptamer
Schematic representation of the design of the activatable aptamers probe (AAP)
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Aptamer
Aptamers are oligonucleotides such as RNA and single-strand deoxyribonucleic acid (ssDNA) or peptide molecules that can bind to their targets with high affinity and specificity due to their specific three-dimensional structures
Advantages of aptamers
Aptamers are produced chemically in a readily scalable process Chemical production process is not prone to viral or bacterial
contamination Non-immunogenic Smaller size allows more efficient entry into biological
compartments
The annual trends in the number of publications of aptamers-related research The term ldquoaptamerrdquo has been utilized for literature search on Thomson Reuters Web of Science
Aptamers in research
ELLINGTON AD SZOSTAK JW In vitro selection of RNA molecules that bind specific ligands[ J] Nature 1990 346( 6287) 818- 822TUERK CGOLD L Systematic evolution of ligands by exponential enrichment RNA ligands to bacteriophage-T4 DNA polymerase[ J] Science1990 249( 4968) 505- 510
SELEX (Systematic evolution of ligands by exponential enrichment)bull First reported by both Goldrsquos group and Szostakrsquos group in 1990
bull SELEX experiment a random sequence oligonucleotide library is synthesized that spans 20ndash100 residues in length and each nucleotide is flanked by constant sequences
bull The pool will frequently contain between 1 times 1013 to 1 times1015
members
Aptamer discovery process
Song K M Aptamers and their biological applications Sensors (Basel)12 612-31(2012)
Various application fields of aptamers
Aptamers in the Clinical Pipeline
JELLINEK DGREEN LSBELL Cet al Inhibition of receptor-binding by high-affinity RNA ligands to vascular endothelial growth-factor[J] Biochemistry199433 ( 34 ) 10450 - 10456 RUCKMAN JGREEN LSBEESON Jet al 2-fluoropyrimi- dine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor ( VEGF ( 165 ) ) -inhibition of receptor binding and VEGF-induced vascular permeability through interac- tions requiring the exon 7-encoded domain[J] J Biol Chem 1998273( 32) 20556 - 20567DlsquoAMICO DJMASONSON HNPATEL Met al Pegaptanib sodium for neovascular age-related macular degeneration-Two-year safety results of the two prospective multicenter controlled clinical trials[J] Ophthalmology2006113( 6) 992 - 1001
Pegaptanibmdashmdashanti-VEGF aptamer
Schematic representation of the design of the activatable aptamers probe (AAP)
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
The annual trends in the number of publications of aptamers-related research The term ldquoaptamerrdquo has been utilized for literature search on Thomson Reuters Web of Science
Aptamers in research
ELLINGTON AD SZOSTAK JW In vitro selection of RNA molecules that bind specific ligands[ J] Nature 1990 346( 6287) 818- 822TUERK CGOLD L Systematic evolution of ligands by exponential enrichment RNA ligands to bacteriophage-T4 DNA polymerase[ J] Science1990 249( 4968) 505- 510
SELEX (Systematic evolution of ligands by exponential enrichment)bull First reported by both Goldrsquos group and Szostakrsquos group in 1990
bull SELEX experiment a random sequence oligonucleotide library is synthesized that spans 20ndash100 residues in length and each nucleotide is flanked by constant sequences
bull The pool will frequently contain between 1 times 1013 to 1 times1015
members
Aptamer discovery process
Song K M Aptamers and their biological applications Sensors (Basel)12 612-31(2012)
Various application fields of aptamers
Aptamers in the Clinical Pipeline
JELLINEK DGREEN LSBELL Cet al Inhibition of receptor-binding by high-affinity RNA ligands to vascular endothelial growth-factor[J] Biochemistry199433 ( 34 ) 10450 - 10456 RUCKMAN JGREEN LSBEESON Jet al 2-fluoropyrimi- dine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor ( VEGF ( 165 ) ) -inhibition of receptor binding and VEGF-induced vascular permeability through interac- tions requiring the exon 7-encoded domain[J] J Biol Chem 1998273( 32) 20556 - 20567DlsquoAMICO DJMASONSON HNPATEL Met al Pegaptanib sodium for neovascular age-related macular degeneration-Two-year safety results of the two prospective multicenter controlled clinical trials[J] Ophthalmology2006113( 6) 992 - 1001
Pegaptanibmdashmdashanti-VEGF aptamer
Schematic representation of the design of the activatable aptamers probe (AAP)
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
ELLINGTON AD SZOSTAK JW In vitro selection of RNA molecules that bind specific ligands[ J] Nature 1990 346( 6287) 818- 822TUERK CGOLD L Systematic evolution of ligands by exponential enrichment RNA ligands to bacteriophage-T4 DNA polymerase[ J] Science1990 249( 4968) 505- 510
SELEX (Systematic evolution of ligands by exponential enrichment)bull First reported by both Goldrsquos group and Szostakrsquos group in 1990
bull SELEX experiment a random sequence oligonucleotide library is synthesized that spans 20ndash100 residues in length and each nucleotide is flanked by constant sequences
bull The pool will frequently contain between 1 times 1013 to 1 times1015
members
Aptamer discovery process
Song K M Aptamers and their biological applications Sensors (Basel)12 612-31(2012)
Various application fields of aptamers
Aptamers in the Clinical Pipeline
JELLINEK DGREEN LSBELL Cet al Inhibition of receptor-binding by high-affinity RNA ligands to vascular endothelial growth-factor[J] Biochemistry199433 ( 34 ) 10450 - 10456 RUCKMAN JGREEN LSBEESON Jet al 2-fluoropyrimi- dine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor ( VEGF ( 165 ) ) -inhibition of receptor binding and VEGF-induced vascular permeability through interac- tions requiring the exon 7-encoded domain[J] J Biol Chem 1998273( 32) 20556 - 20567DlsquoAMICO DJMASONSON HNPATEL Met al Pegaptanib sodium for neovascular age-related macular degeneration-Two-year safety results of the two prospective multicenter controlled clinical trials[J] Ophthalmology2006113( 6) 992 - 1001
Pegaptanibmdashmdashanti-VEGF aptamer
Schematic representation of the design of the activatable aptamers probe (AAP)
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Aptamer discovery process
Song K M Aptamers and their biological applications Sensors (Basel)12 612-31(2012)
Various application fields of aptamers
Aptamers in the Clinical Pipeline
JELLINEK DGREEN LSBELL Cet al Inhibition of receptor-binding by high-affinity RNA ligands to vascular endothelial growth-factor[J] Biochemistry199433 ( 34 ) 10450 - 10456 RUCKMAN JGREEN LSBEESON Jet al 2-fluoropyrimi- dine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor ( VEGF ( 165 ) ) -inhibition of receptor binding and VEGF-induced vascular permeability through interac- tions requiring the exon 7-encoded domain[J] J Biol Chem 1998273( 32) 20556 - 20567DlsquoAMICO DJMASONSON HNPATEL Met al Pegaptanib sodium for neovascular age-related macular degeneration-Two-year safety results of the two prospective multicenter controlled clinical trials[J] Ophthalmology2006113( 6) 992 - 1001
Pegaptanibmdashmdashanti-VEGF aptamer
Schematic representation of the design of the activatable aptamers probe (AAP)
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Song K M Aptamers and their biological applications Sensors (Basel)12 612-31(2012)
Various application fields of aptamers
Aptamers in the Clinical Pipeline
JELLINEK DGREEN LSBELL Cet al Inhibition of receptor-binding by high-affinity RNA ligands to vascular endothelial growth-factor[J] Biochemistry199433 ( 34 ) 10450 - 10456 RUCKMAN JGREEN LSBEESON Jet al 2-fluoropyrimi- dine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor ( VEGF ( 165 ) ) -inhibition of receptor binding and VEGF-induced vascular permeability through interac- tions requiring the exon 7-encoded domain[J] J Biol Chem 1998273( 32) 20556 - 20567DlsquoAMICO DJMASONSON HNPATEL Met al Pegaptanib sodium for neovascular age-related macular degeneration-Two-year safety results of the two prospective multicenter controlled clinical trials[J] Ophthalmology2006113( 6) 992 - 1001
Pegaptanibmdashmdashanti-VEGF aptamer
Schematic representation of the design of the activatable aptamers probe (AAP)
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Aptamers in the Clinical Pipeline
JELLINEK DGREEN LSBELL Cet al Inhibition of receptor-binding by high-affinity RNA ligands to vascular endothelial growth-factor[J] Biochemistry199433 ( 34 ) 10450 - 10456 RUCKMAN JGREEN LSBEESON Jet al 2-fluoropyrimi- dine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor ( VEGF ( 165 ) ) -inhibition of receptor binding and VEGF-induced vascular permeability through interac- tions requiring the exon 7-encoded domain[J] J Biol Chem 1998273( 32) 20556 - 20567DlsquoAMICO DJMASONSON HNPATEL Met al Pegaptanib sodium for neovascular age-related macular degeneration-Two-year safety results of the two prospective multicenter controlled clinical trials[J] Ophthalmology2006113( 6) 992 - 1001
Pegaptanibmdashmdashanti-VEGF aptamer
Schematic representation of the design of the activatable aptamers probe (AAP)
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
JELLINEK DGREEN LSBELL Cet al Inhibition of receptor-binding by high-affinity RNA ligands to vascular endothelial growth-factor[J] Biochemistry199433 ( 34 ) 10450 - 10456 RUCKMAN JGREEN LSBEESON Jet al 2-fluoropyrimi- dine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor ( VEGF ( 165 ) ) -inhibition of receptor binding and VEGF-induced vascular permeability through interac- tions requiring the exon 7-encoded domain[J] J Biol Chem 1998273( 32) 20556 - 20567DlsquoAMICO DJMASONSON HNPATEL Met al Pegaptanib sodium for neovascular age-related macular degeneration-Two-year safety results of the two prospective multicenter controlled clinical trials[J] Ophthalmology2006113( 6) 992 - 1001
Pegaptanibmdashmdashanti-VEGF aptamer
Schematic representation of the design of the activatable aptamers probe (AAP)
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Schematic representation of the design of the activatable aptamers probe (AAP)
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Optical Molecular Imaging with Aptamer-Based Probes
Shi H He X Wang K Wu X Ye X Guo Q Tan W Qing Z Yang X Zhou B Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration Proc Natl Acad Sci USA 2011108
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Aptamer-mediated drug delivery
Omid C Farokhzad Jianjun Cheng1113142 Benjamin A Teply et al Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006103
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Aptamer-mediated drug delivery
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
Problems
bull Time-consuming in selection
CE-SELEX automated screening technologybull Easy to degrade in vivo
Modified nucleoside Capping PEGlyationhellipbull How to illustrate the binding structure
NMRhellipbull Not mature for application
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
- Advance in research of aptamers and related drugs
- Aptamer
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
-
top related